Observed clinical efficacy in the joint treatment of memantine and aricept for the mental and behavioral symptoms of alzheimer's disease
10.3760/cma.j.issn.1008-6315.2017.02.009
- VernacularTitle:美金刚联合盐酸多奈哌齐治疗阿尔茨海默病伴精神行为症状的临床效果观察
- Author:
Meiping WANG
- Keywords:
Alzheimer's disease;
Memantine;
Aricept;
Relevant Outcome Scale for Alzheimer's Disease
- From:
Clinical Medicine of China
2017;33(2):126-130
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the therapeutic effect of combination of memantine and donepezil on cognitive mental symptoms in patients with Alzheimer's disease.Methods Seventy cases elderly patients with Alzheimer's disease were randomly divided into two groups,memantine and donepezil group(treatment group)with 35 cases,donepezil hydrochloride and olanzapine group(control group)with 35 cases.Scoring in before treatment and 6,12 weeks after treatment in application of rosa linked to Alzheimer's disease(ROSA)and the neuropsychiatric Inventory(NPI)assessment,montreal cognitive assessment scale(MoCA scale)were assessed.Results ROSA scores in before treatment and 6,12 weeks after treatment of treatment group and control group was(75.14±17.20)points and(73.97±17.29)points,(89.77±17.14)points and(80.84±15.31)points,(100.30±14.47)points and(89.31±13.30)points,there were statistically significant differences before treatment between the two groups(P＜0.05),there were statistically significant differences 6,12 weeks after treatment inner groups(P＜0.05).MoCA,NPI and NPI care distress comparison between groups differences were not statistically significant(P＞0.05).Conclusion The combined treatment of memantine and donepezil in Alzheimer's disease can improve cognitive function and mental symptoms,communication,etc.The effect of agitation or attack than the control group is significantly different.
